Adma Biologics reported $114.5M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Takeda JPY 1.09T 100B Mar/2026